Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

March 31, 2011

Conditions
SchizophreniaCentral Nervous System DiseasesCognition
Interventions
DRUG

EVP-6124

Arms: 1

DRUG

Placebo

Arm: 3

DRUG

EVP-6124

Arms: 2

Trial Locations (31)

11000

Clinical Site 1, Belgrade

Clinical Site 2, Belgrade

Clinical Site 3, Belgrade

18000

Niš

20850

CBH Health, LLC, Rockville

CRI Worldwide, Willingboro

21005

Vinnytsia

29407

Carolina Clinical Trials, Inc., Charleston

33161

Scientific Clinical Research, Inc., North Miami

34000

Kragujevac

49005

Dnipro

60169

Alexian Brothers Behavioral Health, Hoffman Estates

60640

Uptown Research Institute, Chicago

65014

Odesa

75115

InSite Clinical Research, DeSoto

78756

FutureSearch Clinical Trials, L.P., Austin

91204

Intergrated Medical and Behavioral Associates, Glendale

91403

Schuster Medical Research Institute, Sherman Oaks

92056

Excell Research, Oceanside

92103

University of California, San Diego, San Diego

92108

Affiliated Research Institute, San Diego

95006

Crimea

107076

Moscow

115522

Moscow

163530

Arkhangelsk

190121

Saint Petersburg

355108

Stavropol

420012

Kazan'

37212-8645

Vanderbilt Psychiatric Hospital, Nashville

02660

Kiev

04080

Kiev

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

FORUM Pharmaceuticals Inc

INDUSTRY